Grifols, S.A. $GRFS Shares Acquired by Brandes Investment Partners LP

Brandes Investment Partners LP raised its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 8.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,035,461 shares of the biotechnology company’s stock after purchasing an additional 2,294,113 shares during the quarter. Grifols accounts for approximately 2.3% of Brandes Investment Partners LP’s portfolio, making the stock its 3rd largest position. Brandes Investment Partners LP owned about 4.08% of Grifols worth $253,441,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. R Squared Ltd acquired a new position in shares of Grifols during the second quarter valued at about $95,000. Bessemer Group Inc. boosted its stake in Grifols by 1,693.8% during the 2nd quarter. Bessemer Group Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 11,162 shares during the last quarter. Ascent Group LLC bought a new stake in Grifols during the 2nd quarter worth approximately $141,000. Ballentine Partners LLC raised its stake in shares of Grifols by 48.9% in the second quarter. Ballentine Partners LLC now owns 16,179 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 5,311 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Grifols in the first quarter worth approximately $184,000.

Analyst Ratings Changes

Several brokerages recently issued reports on GRFS. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Wall Street Zen upgraded Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Zacks Research lowered shares of Grifols from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.30.

Grifols Stock Down 0.6%

GRFS opened at $8.80 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 2.64 and a debt-to-equity ratio of 1.20. The stock has a market cap of $6.05 billion, a price-to-earnings ratio of 46.32, a PEG ratio of 0.32 and a beta of 0.69. Grifols, S.A. has a twelve month low of $6.19 and a twelve month high of $11.14. The company’s 50-day moving average price is $9.22 and its two-hundred day moving average price is $9.39.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.